Overview |
bs-9957R |
CREG2 Polyclonal Antibody |
WB, IHC-P, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human CREG2 |
21-120/290 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
200407 |
CREG 2; CREG-2; Cellular repressor of E1A stimulated genes 2; CREG2_HUMAN. |
The adenovirus E1A protein both activates and represses gene expression to promote cellular proliferation and inhibit differentiation. CREG (cellular repressor of E1A-stimulated genes) is a cellular protein that antagonizes transcriptional activation and cellular transformation by E1A. CREG was initially isolated in a yeast two-hybrid screen due to its interaction with the TATA-binding protein, TBP. A member of the CREG family, CREG2 (cellular repressor of E1A-stimulated genes 2) is a novel protein that shares 35% homology with CREG and is expressed at highest levels in brain. CREG2 is a secreted protein containing 290 amino acids whose N-terminus is thought to function as a signal sequence. The gene encoding CREG2 maps to human chromosome 2, which consists of 237 million bases, encodes over 1,400 genes and makes up approximately 8% of the human genome. A number of genetic diseases are linked to genes on chromosome 2 including Harlequin icthyosis, sitosterolemia and Alstr syndrome. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(IHC-P) |
1:50-200 |